Roth Capital Upgrades Unity Biotechnology to Buy, Maintains $4 Price Target

Roth Capital analyst Elemer Piros upgrades Unity Biotechnology (NASDAQ:UBX) from Neutral to Buy and maintains $4 price target.

Roth Capital analyst Elemer Piros upgrades Unity Biotechnology (NASDAQ:UBX) from Neutral to Buy and maintains $4 price target.

Total
0
Shares
Related Posts